>
Sinovac Biotech logo

SVA - Sinovac Biotech Share Price

$6.47 0.0  0.0%

Last Trade - 22/02/19

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £189.6m
Position in Universe th / 6852
Bullish
Bearish
Unlock SVA Revenue
Momentum
Relative Strength (%)
1m -5.79%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
62.9 67.4 72.4 174.3 229.7 246.1 +31.4%
-99.3 -25.7 +8.7
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, SinovacBiotech Ltd. revenues increased 11% to $183.2M. Net lossapplicable to common stockholders totaled $3M vs. income of$18.1M. Revenues reflect an increase in demand for theCompany's products and services due to favorable marketconditions. Net loss reflects Research and developmentexpenses increase from $16.5M to $46.1M (expense), Selling,General & admin increase of 6% to $93.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

SVA Revenue Unlock SVA Revenue

Net Income

SVA Net Income Unlock SVA Revenue

Normalised EPS

SVA Normalised EPS Unlock SVA Revenue

PE Ratio Range

SVA PE Ratio Range Unlock SVA Revenue

Dividend Yield Range

SVA Dividend Yield Range Unlock SVA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
SVA EPS Forecasts Unlock SVA Revenue
Profile Summary

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated March 1, 1999
Public Since November 13, 2009
No. of Shareholders: n/a
No. of Employees: 910
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 98,903,243
Free Float (0.0%)
Eligible for
ISAs
SIPPs
SVA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for SVA
Upcoming Events for SVA
Frequently Asked Questions for Sinovac Biotech
What is the Sinovac Biotech share price?

As of 22/02/19, shares in Sinovac Biotech are trading at $6.47, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the Sinovac Biotech share price performed this year?

Shares in Sinovac Biotech are currently trading at $6.47 and the price has moved by -20.32% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Sinovac Biotech price has moved by -47.63% over the past year.

What are the analyst and broker recommendations for Sinovac Biotech?

Of the analysts with advisory recommendations for Sinovac Biotech, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Sinovac Biotech is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Sinovac Biotech next release its financial results?

Sinovac Biotech is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Sinovac Biotech dividend yield?

Sinovac Biotech does not currently pay a dividend.

Does Sinovac Biotech pay a dividend?

Sinovac Biotech does not currently pay a dividend.

When does Sinovac Biotech next pay dividends?

Sinovac Biotech does not currently pay a dividend.

How do I buy Sinovac Biotech shares?

To buy shares in Sinovac Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Sinovac Biotech?

Shares in Sinovac Biotech are currently trading at $6.47, giving the company a market capitalisation of £n/a.

Where are Sinovac Biotech shares listed? Where are Sinovac Biotech shares listed?

Here are the trading details for Sinovac Biotech:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: SVA
What kind of share is Sinovac Biotech?

We were not able to load our ranking data for Sinovac Biotech

Is there a Sinovac Biotech share price forecast 2021?

We were not able to load any forecast data for Sinovac Biotech.

How can I tell whether the Sinovac Biotech share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sinovac Biotech. Over the past six months, the relative strength of its shares against the market has been -14.63%. At the current price of $6.47, shares in Sinovac Biotech are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Sinovac Biotech PE Ratio?

We were not able to find PE ratio data for Sinovac Biotech.

Who are the key directors of Sinovac Biotech?

Sinovac Biotech's management team is headed by:

WeiDong Yin - CHM
Simon Anderson - IND
Yuk Lam Lo - IND
Nan Wang - CFO
Kenneth Lee - IND
Meng Mei - IND
Shan Fu - IND
Qiang Gao - VPR
Jing Li - VPR
Xiaomei Yin - VPR
Who are the major shareholders of Sinovac Biotech?

Here are the top five shareholders of Sinovac Biotech based on the size of their shareholding:

1Globe capital, L.L.C. Corporation
Percentage owned: 18.72% (18.5m shares)
Yin (Weidong) Individual Investor
Percentage owned: 12.71% (12.6m shares)
SAIF Advisors Limited Private Equity
Percentage owned: 10.9% (10.8m shares)
CDH Utopia Ltd Corporation
Percentage owned: 6.07% (6.00m shares)
Vivo Capital, LLC Venture Capital
Percentage owned: 5.97% (5.90m shares)
Similar to SVA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.